European Commission Approves KRAZATI (adagrasib) as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation

Source :: PR Newswire. January 10, 2024
Publication Year :: 2024
Abstract: SAN DIEGO and ZUG, Switzerland, Jan. 10, 2024 /PRNewswire/ -- https://c212.net/c/link/?t=0&l=en&o=4064737-1&h=1009758736&u=https%3A%2F%2Fwww.mirati.com%2F&a=Mirati+Therapeutics%2C+Inc. (NASDAQ: MRTX), a commercial stage biotechnology company, today announced that the European Commission (EC) granted conditional marketing authorization for [...]

Subjects :: Drug approval
Lung cancer, Non-small cell -- Care and treatment -- Genetic aspects
Business
News, opinion and commentary
Krazati (Medication)

Tools